Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019) - Horwitz, S.M.; Foss, F.M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M.S.; Kim, Y.H.; Weinstock, D.; Lustgarten, S.; Baglio, M.; Youssoufian, H.; et al.